Boehringer Ingelheim Pharmaceuticals
900 Ridgebury Road
Ridgefield, CT 06877
Amy Fry, Vice President Communications and Public Relations
Boehringer Ingelheim Group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 34 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company as been committed to researching, developing, manufacturing an and marketing novel products of high therapeutic value for human and veterinary medicine. In 2004, Boehringer Ingelheim posted net sales of US $10.2 billion (8.2 billion euro) while spending nearly one fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
Chronic obstructive pulmonary disease, chronic inflammatory diseases, antivirals, neurological diseases and stroke.
ALUPENT (metaproterenol sulfate) for bronchial asthma and for reversible bronchospasm associated with bronchitis and emphysema, ATROVENT (ipratropium bromide) and COMBIVENT (ipratropium bromide/albuterol sulfate) for maintenance therapy of brochospasm associated with chronic obstructive pulmonary disease; MICARDIS (telmisartan), CATAPRES (clonidine) and CATAPRES-TTS (clonidine hydrochloride) for treating high blood pressure; FLOMAX (tamsulosin) for treatment of the signs and symptoms of benign prostate hyperplasia (licensed from Yamanouchi Pharmaceuticals, Inc.); MIRAPEX (pramipexole) for the signs and symptoms of idiopathic Parkinson’s disease, PERSANTINE (dipyridamole) and MEXITIL (mexiletine hydrochloride) for managing cardiovascular disease; and VIRAMUNE (nevirpaine for managing HIV infection (marketed by Boehringer Ingelheim affilate Roxane Laboratories, Inc.).
Parent Company: Boehringer Ingelheim Corporation
CT Employees: 1,900
Total Sales Revenue: $4.97 Million ’98
Annual Budget: $902 Million ’98